Rigel Pharmaceuticals (RIGL) Expected to Announce Quarterly Earnings on Tuesday

Rigel Pharmaceuticals (NASDAQ:RIGL) is projected to announce its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Rigel Pharmaceuticals to post earnings of $1.17 per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Rigel Pharmaceuticals Trading Down 2.7%

Shares of RIGL opened at $34.74 on Friday. The company has a current ratio of 2.28, a quick ratio of 2.14 and a debt-to-equity ratio of 0.25. Rigel Pharmaceuticals has a 1 year low of $15.50 and a 1 year high of $52.24. The stock has a market cap of $630.53 million, a PE ratio of 5.63 and a beta of 1.11. The stock has a 50 day simple moving average of $38.17 and a 200-day simple moving average of $37.49.

Insider Activity

In other news, Director Walter H. Moos sold 4,000 shares of the firm’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $36.36, for a total transaction of $145,440.00. Following the completion of the transaction, the director directly owned 12,722 shares in the company, valued at $462,571.92. This trade represents a 23.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.48% of the stock is owned by company insiders.

Institutional Trading of Rigel Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RIGL. Rhumbline Advisers lifted its position in shares of Rigel Pharmaceuticals by 2.1% in the 2nd quarter. Rhumbline Advisers now owns 27,065 shares of the biotechnology company’s stock worth $507,000 after purchasing an additional 555 shares during the period. Deutsche Bank AG increased its position in shares of Rigel Pharmaceuticals by 4.0% during the fourth quarter. Deutsche Bank AG now owns 14,655 shares of the biotechnology company’s stock worth $628,000 after buying an additional 570 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in Rigel Pharmaceuticals by 400.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,275 shares of the biotechnology company’s stock worth $55,000 after buying an additional 1,020 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Rigel Pharmaceuticals by 12.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,434 shares of the biotechnology company’s stock valued at $447,000 after buying an additional 1,149 shares during the period. Finally, Wells Fargo & Company MN boosted its position in Rigel Pharmaceuticals by 1.9% during the fourth quarter. Wells Fargo & Company MN now owns 61,999 shares of the biotechnology company’s stock valued at $2,655,000 after acquiring an additional 1,171 shares during the last quarter. Institutional investors and hedge funds own 66.23% of the company’s stock.

Wall Street Analyst Weigh In

RIGL has been the subject of several research analyst reports. Citigroup reissued a “buy” rating on shares of Rigel Pharmaceuticals in a research note on Wednesday, January 14th. Zacks Research raised shares of Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 18th. Wall Street Zen raised shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, December 21st. Weiss Ratings restated a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group raised shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $23.00 to $42.00 in a research note on Wednesday, November 5th. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Rigel Pharmaceuticals currently has an average rating of “Hold” and an average price target of $43.20.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).